drugset

drugset / Trial / NCT00406237

Pharmacokinetic Study Of Tigecycline In Adult Subjects With Primary Biliary Cirrhosis

NCT00406237 ↗

Phase 1 Completed 8 enrolled Wyeth is now a wholly owned subsidiary of Pfizer

Non-randomizedSingle-groupOpen-label

Summary

Open label, single dose study of the pharmacokinetics of tigecycline in adult subjects with primary biliary cirrhosis (PBC)

Timeline

Start: 2006-12
Primary completion: 2009-03
Completion: 2009-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tigecycline	Small molecule	50 mg	Intravenous

Indications